Search

Your search keyword '"Ozturk, Zafer E."' showing total 16 results
Start Over Author "Ozturk, Zafer E."
16 results on '"Ozturk, Zafer E."'

2. Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Author

Calzavara-Pinton, Piergiacomo, Čelakovská, Jarmila, Lapeere, Hilde, Holzer, Gregor, Al-Ahmad, Mona, Chu, Chia-Yu, Ferrucci, Silvia M., Kataoka, Yoko, Rossi, Mariateresa, Fomina, Daria S., Chung, Wen-Hung, Tzellos, Thrasyvoulos, Fougerousse, Anne-Claire, Wu, Jiangming, Ardeleanu, Marius, and Ozturk, Zafer E.

Published
2023
Full Text
View/download PDF

3. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study

Author

Merola, Joseph F, primary, Chiou, Albert S, additional, During, Emmanuel, additional, Costanzo, Antonio, additional, Foley, Peter, additional, Alfalasi, Amani, additional, Gogate, Shaila, additional, Pinter, Andreas, additional, Dodiuk-Gad, Roni, additional, Simon, Dagmar, additional, Tauber, Marie, additional, Weller, Richard, additional, Pereyra-Rodriguez, Jose-Juan, additional, Ardeleanu, Marius , additional, Wu, Jiangming, additional, and Ozturk, Zafer E, additional

Published
2023
Full Text
View/download PDF

7. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Author

MS Dermatologie/Allergologie, Infection & Immunity, Beck, Lisa A, Thaçi, Diamant, Deleuran, Mette, de Bruin-Weller, Marjolein, Chen, Zhen, Khokhar, Faisal A, Zhang, Meng, Ozturk, Zafer E, Shumel, Brad, MS Dermatologie/Allergologie, Infection & Immunity, Beck, Lisa A, Thaçi, Diamant, Deleuran, Mette, de Bruin-Weller, Marjolein, Chen, Zhen, Khokhar, Faisal A, Zhang, Meng, Ozturk, Zafer E, and Shumel, Brad

Published
2022

8. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy:baseline characteristics of participants on the EUROSTAD prospective observational study

Author

Bruin-Weller, Marjolein de, Pink, Andrew E., Patrizi, Annalisa, Gimenez-Arnau, Ana M., Agner, Tove, Roquet-Gravy, Pierre Paul, Ferrucci, Silvia M., Arenberger, Petr, Svensson, Ake, Schuttelaar, Marie L.A., Nosbaum, Audrey, Jayawardena, Shyamalie, Rizova, Elena, Ardeleanu, Marius, Eckert, Laurent, Ozturk, Zafer E., Bruin-Weller, Marjolein de, Pink, Andrew E., Patrizi, Annalisa, Gimenez-Arnau, Ana M., Agner, Tove, Roquet-Gravy, Pierre Paul, Ferrucci, Silvia M., Arenberger, Petr, Svensson, Ake, Schuttelaar, Marie L.A., Nosbaum, Audrey, Jayawardena, Shyamalie, Rizova, Elena, Ardeleanu, Marius, Eckert, Laurent, and Ozturk, Zafer E.

Abstract

Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator’s Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.

Published
2021

10. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.

Author

Beck, Lisa A., Thaçi, Diamant, Deleuran, Mette, de Bruin-Weller, Marjolein, Chen, Zhen, Khokhar, Faisal A., Zhang, Meng, Ozturk, Zafer E., and Shumel, Brad

Subjects
ATOPIC dermatitis, DUPILUMAB, LABORATORY safety, TERMINATION of treatment, PATIENT compliance
Abstract

Most systemic agents used for moderate-to-severe atopic dermatitis (AD) may lead to adverse events requiring routine laboratory monitoring, increasing patient burden and possibly decreasing treatment adherence. To evaluate clinical laboratory findings in adults with moderate-to-severe AD treated with dupilumab up to 3 years. LIBERTY AD OLE (NCT01949311) was a phase 3, multicenter, open-label extension study in adults with moderate-to-severe AD receiving dupilumab 300 mg weekly. 2,677 patients were treated up to 3 years. No clinically meaningful changes in mean hematology/serum chemistry parameters from baseline were observed. Few laboratory abnormalities were reported as treatment-emergent adverse events. Serious events included one event each of thrombocytopenia, hematuria, and hemolytic anemia, all unrelated to treatment. Abnormalities leading to treatment withdrawal included thrombocytopenia (one patient), increased hepatic enzymes (two patients), and blood creatine phosphokinase increased (one patient). No patients had Grade 3 anemia or Grade 3/4 thrombocytopenia; one patient had Grade 3 neutropenia (Week 100); two patients had Grade 3 eosinophilia (baseline visit); no eosinophil abnormalities were associated with clinically symptomatic events/permanent treatment discontinuation. Dupilumab treatment of adults with moderate-to-severe AD up to 3 years showed no clinically meaningful changes in mean laboratory parameters, supporting continuous long-term use without laboratory monitoring. NCT01949311 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Author

Bruin-Weller, Marjolein de, primary, Pink, Andrew E., additional, Patrizi, Annalisa, additional, Gimenez-Arnau, Ana M., additional, Agner, Tove, additional, Roquet-Gravy, Pierre-Paul, additional, Ferrucci, Silvia M., additional, Arenberger, Petr, additional, Svensson, Ake, additional, Schuttelaar, Marie L.A, additional, Nosbaum, Audrey, additional, Jayawardena, Shyamalie, additional, Rizova, Elena, additional, Ardeleanu, Marius, additional, Eckert, Laurent, additional, and Ozturk, Zafer E., additional

Published
2021
Full Text
View/download PDF

13. Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology

Author

Paller, Amy S, primary, Guttman-Yassky, Emma, additional, Irvine, Alan D, additional, Baselga, Eulalia, additional, de Bruin-Weller, Marjolein, additional, Jayawardena, Shyamalie, additional, Zhang, Annie, additional, Mina-Osorio, Paola, additional, Rizova, Elena, additional, and Ozturk, Zafer E, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results